TBCRC 033 UAB 1568: A Randomized Phase II study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage 1 HER2-Positive Breast Cancer (ATEMPT Trial)

Grant

Date/time Interval

  • December 23, 2015 - December 22, 2018
  • Total Award Amount

  • 76000.00
  • Direct Costs

  • 60317.00
  • Sponsor Award Id

  • Contributor

  • Stringer-Reasor M.D., Erica   Investigator